Tafasitamab has shown potent activity in preclinical studies involving lymphoma and leukemia models, including 100‒1000‐fold enhanced ADCC relative to an anti‐CD19 IgG1 analog in vitro.41, 42. Here, CD19 is linked to lymphoma.